Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries AmerisourceBergen Provides Update on Capital Deployment By: AmerisourceBergen Corporation via Business Wire May 12, 2022 at 08:01 AM EDT Resuming share repurchases with excess free cash flow Remains committed to investment grade credit ratings AmerisourceBergen Corporation (NYSE: ABC) today announced that it is resuming share repurchases with excess free cash flow in accordance with the company’s disciplined approach to capital allocation. The company remains fully committed to maintaining its investment grade credit ratings, which involves paying down $2 billion in debt within two years of the June 2021 acquisition of Alliance Healthcare. As noted during its most recent earnings call, the company is on track to achieve this debt paydown by March 2023, ahead of the two-year commitment. Cautionary Statements Regarding Forward Looking Statements The preceding descriptions of the Company’s approach to capital allocation constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, AmerisourceBergen undertakes no obligation to publicly update forward-looking statements. Investors should read the important risk factors described in AmerisourceBergen’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission. About AmerisourceBergen AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005620/en/Contacts Bennett S. Murphy Senior Vice President, Investor Relations 610-727-3693 bmurphy@amerisourcebergen.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
AmerisourceBergen Provides Update on Capital Deployment By: AmerisourceBergen Corporation via Business Wire May 12, 2022 at 08:01 AM EDT Resuming share repurchases with excess free cash flow Remains committed to investment grade credit ratings AmerisourceBergen Corporation (NYSE: ABC) today announced that it is resuming share repurchases with excess free cash flow in accordance with the company’s disciplined approach to capital allocation. The company remains fully committed to maintaining its investment grade credit ratings, which involves paying down $2 billion in debt within two years of the June 2021 acquisition of Alliance Healthcare. As noted during its most recent earnings call, the company is on track to achieve this debt paydown by March 2023, ahead of the two-year commitment. Cautionary Statements Regarding Forward Looking Statements The preceding descriptions of the Company’s approach to capital allocation constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, AmerisourceBergen undertakes no obligation to publicly update forward-looking statements. Investors should read the important risk factors described in AmerisourceBergen’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission. About AmerisourceBergen AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005620/en/Contacts Bennett S. Murphy Senior Vice President, Investor Relations 610-727-3693 bmurphy@amerisourcebergen.com
Resuming share repurchases with excess free cash flow Remains committed to investment grade credit ratings
AmerisourceBergen Corporation (NYSE: ABC) today announced that it is resuming share repurchases with excess free cash flow in accordance with the company’s disciplined approach to capital allocation. The company remains fully committed to maintaining its investment grade credit ratings, which involves paying down $2 billion in debt within two years of the June 2021 acquisition of Alliance Healthcare. As noted during its most recent earnings call, the company is on track to achieve this debt paydown by March 2023, ahead of the two-year commitment. Cautionary Statements Regarding Forward Looking Statements The preceding descriptions of the Company’s approach to capital allocation constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, AmerisourceBergen undertakes no obligation to publicly update forward-looking statements. Investors should read the important risk factors described in AmerisourceBergen’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission. About AmerisourceBergen AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 42,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005620/en/
Bennett S. Murphy Senior Vice President, Investor Relations 610-727-3693 bmurphy@amerisourcebergen.com